enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Ruxolitinib - Wikipedia

   en.wikipedia.org/wiki/Ruxolitinib

   Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

3. Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock - AOL

   www.aol.com/incytes-jakafi-demand-strong-analyst...

   Jakafi (ruxolitinib) net product revenues increased to $741.18 million, up 16% year over year, primarily due to a 10% increase in total demand. Guidance: Incyte forecasts 2024 Jakafi revenue of $2 ...

4. Prescription drug prices in the United States - Wikipedia

   en.wikipedia.org/wiki/Prescription_drug_prices...

   Prescription drug list prices in the United States continually are among the highest in the world. [1] [2] The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015.

5. FDA approves Incyte's treatment for chronic graft-versus-host ...

   www.aol.com/news/fda-approves-incytes-treatment...

   Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood d FDA approves Incyte's treatment for chronic graft-versus-host disease Skip to ...

6. Jakafi® (ruxolitinib) Prescribing Information Updated with ...

   www.aol.com/news/2013-06-12-jakafi-ruxolitinib...

   The prescribing information for Jakafi now includes a new recommended starting dose of 5 mg twice daily of Jakafi for patients with baseline platelet counts between 50-100 x 10 9 /L (50,000 to ...

7. Primary myelofibrosis - Wikipedia

   en.wikipedia.org/wiki/Primary_myelofibrosis

   In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. [24] [25] Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of ...

8. New Data for Jakafi® (ruxolitinib) Presented at the 2012 ...

   www.aol.com/news/2012-12-10-new-data-for-jakafi...

   In this study, where twice as many patients were randomized to Jakafi (146) as to placebo (73), there were 14 percent (n=20) deaths in the group treated with Jakafi and 22 percent (n=16) in the ...

9. Wholesale acquisition cost - Wikipedia

   en.wikipedia.org/wiki/Wholesale_acquisition_cost

   Wholesale acquisition cost is the price of a medication set by a pharmaceutical manufacturer in the United States when selling to a wholesaler. [1] Generally 20% is added to create the average wholesale price .